Cancer Research · 2008 · 55 citations · 30 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyHelper T Cell SubsetsImmune ResponseT Cell Responses To TumorsTumor AntigensAdaptive Antitumor ImmunityCd4 Positive T Cell ResponsesCd4 Positive T CellsCd4+ T Helper Cell ResponsesImmunodominant AntigensPeptide EpitopesSynthetic Peptide AntigensT-cell Epitopes
Tumorigenesis is frequently associated with mutation and overexpression of p53, which makes it an attractive target antigen for T cell-mediated immunotherapy of cancer. However, the magnitude and breadth of the p53-specific T-cell repertoire may be restricted due to the ubiquitous expression of wild-type p53 in normal somatic tissues. In view of the importance of the CD4+ T-helper cell responses in effective antitumor immunity, we have analyzed and compared the p53-specific reactivity of this T cell subset in p53+/+ and p53-/- C57Bl/6 mice. This response was found to be directed against the same three immunodominant epitopes in both mouse types. Fine-specificity, magnitude, and avidity were not affected by self-tolerance. Immunization of p53-/- and p53+/+ mice with synthetic peptide vaccines comprising the identified epitopes induced equal levels of Th1 immunity. Our findings imply that the p53-specific CD4+ T-cell repertoire is not restricted by self-tolerance and is fully available for the targeting of cancer.
30
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Lawrence A. Donehower, Michele Harvey, Betty L. Slagle et al. · Nature · 1992 · 4.7K citations
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Kenneth E. Hung, Robert J. Hayashi, Anne Lafond-Walker et al. · The Journal of Experimental Medicine · 1998 · 1.3K citations · Full text
Life Sciences, Immunology, Oncology +17
p53 Antibodies in the sera of patients with various types of cancer: a review.
Thierry Soussi · PubMed · 2000 · 556 citations
Life Sciences, Immunology, Oncology +15